Permanent product Record

RYSE

Jay's Half & Half Pre

CURRENTRecord last observed August 3, 2026high-stim

RYSE Jay's Half & Half Pre has a current Record. Last observed August 3, 2026. The current public formula contains 7 declared ingredient lines. Comparable formula history is not yet available.

Current Record

The current declared formula.

Printed label wording stays separate from FormulaSignal's normalized identity. Current formula observed August 3, 2026.

Serving size
Not recorded
Servings
Not recorded
Caffeine
200 mg per serving
Formula scope
PRODUCT WIDE
RYSE Jay's Half & Half Pre, current declared formula observed August 3, 2026. Each row gives the printed label wording, the declared amount, and FormulaSignal's normalized identity.
Original label wordingDeclared amountNormalized identity
Potassium80 mgpotassium
L-Citrulline6 gl-citrulline
Beta Alanine5 gbeta-alanine
Inosistol-stabilized Arginine Silicate (as Nitrosigine)1.5 ginositol-stabilized arginine silicate
Caffeine Anhydrous200 mgcaffeine
Dihydrocapsiate (as Capsiatra)130 mgdihydrocapsiate as capsiatra
Methylliberine 40% (as Dynamine)62.5 mgmethylliberine 40% as dynamine

Serving economics

Facts and calculations stay labeled.

Reliable serving economics are not available for this Record.

Historical timeline

Comparable formula states.

Dates below are observation dates. They are not exact reformulation dates.

Historical formula evidence is not yet sufficient for a reliable comparison. This does not establish that the product never changed.

Confirmed Signals

Reviewed changes in the public Record.

No confirmed public Signal is associated with this product. This is not a claim that the product never changed.

Research-dose context

Selected evidence, not a universal effective dose.

These comparisons retain the studied protocol, source, and limitations. They do not establish safety, effectiveness, or a dose recommendation for this product.

A1

L-citrulline

Product declaration
L-Citrulline: 6 g
Selected studied range
3000 to 9000 mg
Protocol and duration
per day, in the studies NIH ODS summarizes
Studied context
Studied as a nitric-oxide pathway precursor (converted to arginine via the urea cycle) for aerobic exercise performance measures such as oxygen-uptake (VO2) kinetics, blood lactate, and rate of perceived exertion, and for acute resistance-exercise performance and muscle oxygenation. NIH ODS describes evidence for enhancing performance as limited, with few studies and conflicting results.
Limitations
A 2022 systematic review/meta-analysis found no significant benefit for endurance-performance outcomes specifically. A single 8 g acute dose did not enhance isometric force production, muscle endurance, or muscle-oxygenation parameters in one resistance-exercise study. NIH ODS characterizes overall performance-enhancement evidence as limited.

Selected evidence: NIH ODS, Dietary Supplements for Exercise and Athletic Performance · Open source

A2

Beta-alanine

Product declaration
Beta Alanine: 5 g
Selected studied range
4000 to 6000 mg
Protocol and duration
per day in divided doses, for at least 2 to 4 weeks, not as a single pre-workout dose
Studied context
Studied for high-intensity exercise capacity in the 60-240 second range via elevation of muscle carnosine, which acts as an intracellular pH buffer against acidosis. ISSN 2015 position stand: greatest performance benefits in "open end-point" tasks/time trials lasting 1-4 minutes; some benefit noted in aerobic exercise up to roughly 25 minutes; attenuation of neuromuscular fatigue, particularly noted in older adults.
Limitations
Strength/resistance-training outcomes remain mixed; training volume may increase without a clear strength gain. Tasks under 60 seconds do not show benefit. Endurance benefit beyond about 25 minutes is not established. Long-term safety data beyond roughly a year, and effects in special/tactical populations, are flagged as needing more research.

Selected evidence: ISSN position stand on beta-alanine, 2015 · Open source

A2

Caffeine

Product declaration
Total caffeine from all declared sources: 200 mg
Selected studied range
140 to 420 mg
Protocol and duration
2 to 6 mg per kg body mass, 15 to 60 minutes before exercise, shown here for a 70 kg adult
Studied context
Studied for endurance-type aerobic exercise (moderate to large ergogenic effect, most consistent evidence category per ISSN 2021), muscular endurance and movement velocity in resistance exercise (small to moderate effects), sprinting/jumping/throwing (2-7% improvements), and cognitive attention/vigilance under fatigue. NIH ODS notes it "might enhance performance in endurance-type activities... And intermittent, long-duration activities."
Limitations
Minimal effective dose remains unclear. Repeated-sprint performance benefit is inconsistent and the ISSN position stand says this "requires further research." Effects of habitual/chronic caffeine use on the ergogenic response are described as equivocal.

Selected evidence: ISSN position stand on caffeine and exercise performance, 2021, with NIH ODS · Open source

Cautions and regulatory records

A filing and a documented risk are not the same thing.

These attach to declared ingredients, not to this product as a whole. Nothing here establishes that the product is safe or unsafe. Talk with a qualified health professional.

No documented caution is recorded against the declared ingredients on this Record. That is not a finding that the product is safe.

Where the sources disagree

What we could not read cleanly.

A disagreement between sources is recorded rather than smoothed into one confident number. None of these is a Signal.

No source conflict is recorded on this Record. That is not a claim that every source agrees, only that none we read disagreed.

Evidence

Audit the material claims.

  • RYSE

    P1 current formula source · observed August 3, 2026 · accessed August 3, 2026

    Open source evidence

Go deeper

Ask now, or keep watch.

No released consumer report is available for this product. Browse Reports.